EU Healthcare Professionals​

This is an international website for NERLYNX® dedicated to EU Healthcare professionals ​​(outside the UK and ROI).

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that: 

I am a Healthcare Professional in the EU (outside the UK and ROI) and I have read the information above​, the Legal Notice and the Privacy Policy

Patients / Non EU Healthcare Professionals

This is an international website for NERLYNX® dedicated to EU Healthcare Professionals (outside the UK and ROI)

I am a patient or a Healthcare Professional outside the EU.

https://www.pierre-fabre.com/en
Image
heading-Nerlynx-Neratinib--HER2-Breast-Cancer

Mechanism of action

Reading time: 2 min

NERLYNX® is a small molecule that provides irreversible, intracellular pan-HER signaling inhibition1,9-14

Trastuzumab, pertuzumab and trastuzumab emtansine share a common target, the extracellular domains of the HER2 receptor.1,9-11 NERLYNX® has a different mechanism of action.1,9,10 

By irreversibly binding to the intracellular domain of all active HER receptors, HER1, HER2 and HER4, NERLYNX ensures steady and prolonged blockade of HER signalling.9-13

HER, human epidermal growth factor receptor.

 

 

Image
This is a simplified illustration of the mechanism of action.


This is a simplified illustration of the mechanism of action.

NERLYNX® Mechanism of action video

 

In HER2+/HR+ patients, NERLYNX® in combination with endocrine therapy addresses HER2-ER crosstalk by targeting both signaling pathways9,12,14-20

Image
Nerlynx-Neratinib--HER2-Breast-Cancer-Mechanism-of-action-2

This is a simplified illustration of the mechanism of action, that only features one of the HER2 receptors.

 

The family of human epidermal growth factor receptors (HER1, HER2, HER3 and HER4) play a central role in the pathogenesis of several cancers.14
The estrogen receptor and the HER2 signaling pathways are the dominant drivers of cell proliferation in the majority of breast cancers.16,17

While endocrine therapy blocks the estrogen signaling pathway, this can lead to crosstalk between the estrogen receptor and the HER2 receptor, which in turn can lead to upregulation of the HER2 signaling pathway.17-20

The addition of NERLYNX® to endocrine therapy prevents this crosstalk, forming a dual blockade of both HER2 and ER signaling pathways, resulting in permanent inhibition of cancer cell growth.9,12,14

ER, estrogen receptor; HER, human epidermal growth factor receptor; HR, hormone receptor.

Contenu de la pop in (ici, un H3)

A noter que le contenu de la pop in est prise en compte pour le SEO.

Il est donc nécessaire de bien baliser les titres. Nous conseillons d'utiliser un H2 ou un H3 (pas de H1).